Navigation Links
Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
Date:9/7/2011

LAUSANNE, Switzerland, and MALVERN, Pennsylvania, September 7, 2011 /PRNewswire/ --

Debiopharm Group™ (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascenta Therapeutics, Inc. (Ascenta), a privately-held, biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer, have entered into an exclusive worldwide license agreement concerning the development and commercialization of AT-406 (called Debio 1143 by Debiopharm) a small molecule IAP inhibitor currently in phase I development. By targeting inhibitors of apoptosis proteins, AT-406 (or Debio 1143) can induce cancer cell death and/or potentiate the efficacy of other treatments and is expected to be effective in the treatment of various cancers in combination with anti-cancer therapies.


"We are very excited about this collaboration with Ascenta Therapeutics. This company has an impressive scientific team and expertise in the field of apoptosis", said Dr Rolland-Yves Mauvernay, president and founder of Debiopharm S.A., who added "it should be possible to combine AT-406 (or Debio 1143) with other pro-apoptotic agents, which can potentially bring huge benefits to patients by enhancing the efficiency of the treatment."

"Ascenta is pleased to form this partnership with Debiopharm, a company that has demonstrated a commitment to and expertise in the development of medicines to help cancer patients", noted Dr. Mel Sorensen, President and CEO of Ascenta.

About AT-406

AT-406 is an orally available small molecule that neutralizes major inhibitors of apoptosis. Apoptosis, or "programmed cell death," is a precisely regulated, complex process ensuring that defective, damaged or superfluous cells are eliminated. Evasion of apoptosis is a hallmark of cancer, enabling cancer cells to live indefinitely and grow uncontrollably. Most current cancer therapies
'/>"/>

SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Japanese Cancer Association and Debiopharm Honour Japanese Research
2. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
6. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
7. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
8. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
9. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
10. Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
11. INC Research and Debiopharm Group(TM) Announce Strategic Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 Navitas, a leading Regulatory Service ... America hub in Bogota, Colombia . Navitas, ... the many benefits provided by Colombia , the third ... Logo - http://photos.prnewswire.com/prnh/20150703/228239LOGO ... location, allows US based clients to communicate with Navitas regulatory professionals in ...
(Date:7/5/2015)... ... July 06, 2015 , ... For many years, metal-on-quartz filters were the ... machine such as a Varian Cary 4000-7000, a Perkin Elmer 800-1100 or a Shimadzu ... even NIST used them for their SRM-2031 series going back for many years. Unfortunately, ...
(Date:7/3/2015)... 3, 2015 ... osoitteessa  http://www.openinnovationinscience.at Wienissä pidettävään ... Science" -jatkokoulutusohjelmaan 22.7.2015 asti.  ... tekemän, kansainvälisiä tutkijoita ja tiedemiehiä ... suurinta haastetta ovat kannustimien puute ...
(Date:7/3/2015)... ... 2015 , ... The global failure analysis market is expected to reach $7,147.0 ... market is expected to grow at the highest CAGR of 8.46%; its growth is ... research labs and academic institutions for root cause analysis of failure. The market based ...
Breaking Biology Technology:Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 2Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 3FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 2FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 3Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5
... Caliper Life Sciences, Inc. (NASDAQ: CALP ... drug discovery and life sciences research for personalized medicine, ... meeting on May 17th and 18th.  This annual event ... diagnostics to discuss the technologies and discoveries that are ...
... ROCKVILLE, Md., May 5, 2011 Vanda Pharmaceuticals Inc. ... focused on the development and commercialization of products for ... results for the first quarter ended March 31, 2011. ... progress we have made to date in 2011," said ...
... PASADENA, Calif., May 4, 2011 Highlights ... from Operations ("FFO") Per Share (Diluted) Attributable to Alexandria Real ... 2011 Losses on Early Extinguishment of Debt, Up 6% Compared ... First Quarter 2011 Earnings Per Share (Diluted) Attributable to ...
Cached Biology Technology:Caliper Owners Group and Investor Meeting to Highlight Technologies Enabling Personalized Medicine 2Vanda Pharmaceuticals Reports First Quarter 2011 Results 2Vanda Pharmaceuticals Reports First Quarter 2011 Results 3Vanda Pharmaceuticals Reports First Quarter 2011 Results 4Vanda Pharmaceuticals Reports First Quarter 2011 Results 5Vanda Pharmaceuticals Reports First Quarter 2011 Results 6Vanda Pharmaceuticals Reports First Quarter 2011 Results 7Vanda Pharmaceuticals Reports First Quarter 2011 Results 8Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 2Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 3Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 4Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 5Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 6Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 7Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 8Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 9Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 10Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 11Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 12Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 13Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 14Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 15Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 16
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... has announced the addition of the "Natural ... Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image ... to their offering. The key vendors ... Google, HP, IBM Corporation, Microsoft Corporation, NetBase Solutions, ...
(Date:6/29/2015)... 2015 Research and Markets( ... "Latin America Biomedical Sensors Market - Growth, Trends & ... The Latin America Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:6/24/2015)... 2015 The biologics safety testing market is ... the market include growth of the pharmaceutical and biological ... Over the years, the number of drug approvals in ... the FDA approved 225 drug applications and Health Canada ... Europe accounted for 3,822 of the pharmaceutical ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... new study in mice, a scientific collaboration centered at ... signaling breakdown in Angelman syndrome, a disorder that affects ... seizures, and other problems. With the new understanding, the ... works to restore neural functions impaired by the disease. ...
... FRANCISCO February 12, 2013 New findings from a ... predict whether a person is likely to develop age-related macular ... than nine million Americans, these genes do not predict how ... most widely used to treat the "wet" form of AMD. ...
... New Geology science posted online ahead of ... several sites in the U.S., as well as work ... southeastern Pacific, South Africa, and Mars. Tectonics, flooding, carbon ... Brief highlights follow. Papers cover , 1. ...
Cached Biology News:Study in mice yields Angelman advance 2Study in mice yields Angelman advance 3Study in mice yields Angelman advance 4Major clinical trial finds no link between genetic risk factors and 2 top wet AMD treatments 2The Geological Society of America Journal Geology: Dynamic geoscience 2The Geological Society of America Journal Geology: Dynamic geoscience 3The Geological Society of America Journal Geology: Dynamic geoscience 4The Geological Society of America Journal Geology: Dynamic geoscience 5The Geological Society of America Journal Geology: Dynamic geoscience 6The Geological Society of America Journal Geology: Dynamic geoscience 7The Geological Society of America Journal Geology: Dynamic geoscience 8The Geological Society of America Journal Geology: Dynamic geoscience 9The Geological Society of America Journal Geology: Dynamic geoscience 10The Geological Society of America Journal Geology: Dynamic geoscience 11The Geological Society of America Journal Geology: Dynamic geoscience 12The Geological Society of America Journal Geology: Dynamic geoscience 13The Geological Society of America Journal Geology: Dynamic geoscience 14The Geological Society of America Journal Geology: Dynamic geoscience 15
... Capping system features the Vaccinia ... the components needed to produce ... end of di- or triphosphate ... high efficiency capping (virtually 100%) ...
Extracti-Gel D Detergent Removing Gel...
... provides high speed and excellent temperature uniformity. ... TGradient Thermocycler can be run without any ... silver block for 48 or 96 wells. ... or in-situ applications are available. The High ...
Designed for use with the Agencourt SprintPrep 384 kit and all MCPrep reagent kits. Used with flat bottom 96-well microplates such as deep well plates used to culture bacteria....
Biology Products: